Edaravone Dexborneol in acute ischemic stroke patients treated with combined intravenous thrombolysis and mechanical thrombectomy for large vessel occlusion
Patients treated with Edaravone Dexborneol were associated with better functional outcomes three months after stroke onset compared to those who did not receive the treatment. These findings may be related to the drug's anti-inflammatory properties; however, randomized controlled trials are needed to confirm efficacy in patients undergoing MT combined with IVT.
Authors
- Xiaozhong Peng (ORCID: https://orcid.org/0000-0002-9592-9554)
- Wei Jiang (ORCID: https://orcid.org/0000-0003-0083-0322)
- Hao Li (ORCID: https://orcid.org/0000-0002-8865-7351)
- Hongxu Zhang (ORCID: https://orcid.org/0000-0001-9178-4143)
- Mengjie Zou (ORCID: https://orcid.org/0009-0006-4796-4968)
- Ruilong Wang (ORCID: https://orcid.org/0009-0002-9369-0284)
Institutions
- Harbin Medical University (CN)
- Wuhan Wudong Hospital (CN)
- Xian Central Hospital (CN)
- Third Affiliated Hospital of Harbin Medical University (CN)
- Shenyang 242 Hospital (CN)
Publication Details
- Journal
- Frontiers in Neurology
- Published
- 2025-10-21
- DOI
- https://doi.org/10.3389/fneur.2025.1681859
- Citations
- 1
- Primary Topic
- Acute Ischemic Stroke Management
- Type
- article
- Field-Weighted Citation Impact
- 1.35